Journal article

Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: A retrospective, multicenter analysis

MJ Styler, P Crilley, J Biggs, J Moul, E Copelan, D Topolsky, B Avalos, S Penza, P Sabol, K Downs, J Szer, I Brodsky, DI Marks

BONE MARROW TRANSPLANTATION | STOCKTON PRESS | Published : 1996

Abstract

Veno-occlusive disease continues to be a significant cause of morbidity and early mortality following bone marrow transplantation. This study retrospectively analyzes the incidence and risk factors for severe VOD in 350 patients treated with 4 days of busulfan (total 16 mg/kg) and 2 days of cyclophosphamide (120 mg/kg) at four marrow transplant centers. Using the criteria defined by McDonald et al (Hepatology 1984; 4: 116-122), 93/350 (27%) developed VOD (11% mild, 5% moderate and 11% severe). Multivariate analysis revealed the following risk factors to be significantly associated with severe VOD: pretransplant transaminase and alkaline phosphatase elevation, ciprofloxacin antibiotic prophyl..

View full abstract